

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

JOHNSON & JOHNSON
Form 10-Q/A
May 15, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q/A

(X) Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 30, 2003

or

() Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the for the transition period from to

Commission file number 1-3215

JOHNSON & JOHNSON
(Exact name of registrant as specified in its charter)

NEW JERSEY 22-1024240
(State or other jurisdiction of (I.R.S. Employer
Incorporation or organization) Identification No.)

One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933
(Address of principal executive offices)

Registrant's telephone number, including area code (732) 524-0400

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes (X) No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

On April 25, 2003, 2,968,820,767 shares of Common Stock, \$1.00 par value, were outstanding.

EXPLANATORY NOTE:

This Form 10-Q/A amends Part I, Item 1 - Financial Statements: Consolidated Statements of Cash Flows for the fiscal three months ended March 30, 2003 and March 31, 2002 of the Quarterly Report on Form 10-Q filed by Johnson & Johnson on May 14, 2003. This statement is solely amending certain cash flow amounts related to financing activities. Net cash flows from operating activities was \$2,036 million and Net cash used by financing activities was \$1,009 million for the three month period ended March 30, 2003.

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

JOHNSON & JOHNSON AND SUBSIDIARIES

TABLE OF CONTENTS

Part I - Financial Information	Page No.
Item 1. Financial Statements	
Consolidated Balance Sheets - March 30, 2003 and December 29, 2002	3
Consolidated Statements of Earnings for the Fiscal Three Months Ended March 30, 2003 and March 31, 2002	5
Consolidated Statements of Cash Flows for the Fiscal Three Months Ended March 30, 2003 and March 31, 2002	6
Notes to Consolidated Financial Statements	7
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	12
Item 3. Quantitative and Qualitative Disclosures About Market Risk	17
Item 4. Controls and Procedures	17
Part II - Other Information	
Item 1 - Legal Proceedings	18
Item 5 - Exhibits and Reports on Form 8-K	21
Signatures	22

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

2

Part I - FINANCIAL INFORMATION

Item 1 - Financial Statements

JOHNSON & JOHNSON AND SUBSIDIARIES
 CONSOLIDATED BALANCE SHEETS
 (Unaudited; Dollars in Millions)

ASSETS

	March 30, 2003	December 29, 2002
Current Assets:		
Cash and cash equivalents	\$ 3,061	2,894
Marketable securities	4,786	4,581
Accounts receivable, trade, less allowances for doubtful accounts \$188(2002 - \$191)	5,836	5,399
Inventories (Note 4)	3,541	3,303
Deferred taxes on income	1,388	1,419
Prepaid expenses and other receivables	1,859	1,670
Total current assets	20,471	19,266
Marketable securities, non-current	121	121
Property, plant and equipment, at cost	14,899	14,314
Less accumulated depreciation	6,100	5,604
	8,799	8,710
Intangible assets, gross (Note 5)	11,647	11,355
Less accumulated amortization	2,222	2,109
Intangible assets, net	9,425	9,246
Deferred taxes on income	286	236
Other assets	2,892	2,977
Total assets	\$41,994	40,556

See Notes to Consolidated Financial Statements

3

JOHNSON & JOHNSON AND SUBSIDIARIES

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

CONSOLIDATED BALANCE SHEETS (Unaudited; Dollars in Millions)

LIABILITIES AND SHAREHOLDERS' EQUITY

	March 30, 2003	December 29, 2002
Current Liabilities:		
Loans and notes payable	\$ 2,103	2,117
Accounts payable	3,077	3,621
Accrued liabilities	4,248	3,820
Accrued salaries, wages and commissions	691	1,181
Taxes on income	1,338	710
Total current liabilities	11,457	11,449
Long-term debt	2,004	2,022
Deferred tax liability	573	643
Employee related obligations	2,005	1,967
Other liabilities	1,919	1,778
Shareholders' equity:		
Preferred stock - without par value (authorized and unissued 2,000,000 shares)	-	-
Common stock - par value \$1.00 per share (authorized 4,320,000,000 shares; issued 3,119,842,000 shares)	3,120	3,120
Note receivable from employee stock ownership plan	(18)	(25)
Accumulated other comprehensive income (Note 8)	(818)	(842)
Retained earnings	27,852	26,571
	30,136	28,824
Less common stock held in treasury, at cost (150,951,000 & 151,547,000 shares)	6,100	6,127
Total shareholders' equity	24,036	22,697
Total liabilities and shareholders' equity	\$41,994	40,556

See Notes to Consolidated Financial Statements

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

CONSOLIDATED STATEMENTS OF EARNINGS (Unaudited; dollars & shares in millions except per share figures)

	Fiscal Quarter Ended			
	March 30, 2003	Percent to Sales	March 31, 2002	Percent to Sales
Sales to customers (Note 6)	\$9,821	100.0	8,743	100.0
Cost of products sold	2,722	27.7	2,457	28.1
Gross Profit	7,099	72.3	6,286	71.9
Selling, marketing and administrative expenses	3,253	33.1	2,843	32.5
Research expense	936	9.5	831	9.5
Purchased in-process research and development	18	.2	-	-
Interest income	(38)	(.4)	(76)	(.9)
Interest expense, net of portion capitalized	38	.4	34	.4
Other (income) expense, net	(37)	(.3)	33	.4
	4,170	42.5	3,665	41.9
Earnings before provision for taxes on income	2,929	29.8	2,621	30.0
Provision for taxes on income (Note 3)	859	8.7	787	9.0
NET EARNINGS	\$2,070	21.1	1,834	21.0
NET EARNINGS PER SHARE (Note 7)				
Basic	\$.70		.60	
Diluted	\$.69		.59	
CASH DIVIDENDS PER SHARE	\$.205		.18	
AVG. SHARES OUTSTANDING				
Basic	2,968.4		3,042.0	
Diluted	3,018.5		3,115.4	

See Notes to Consolidated Financial Statements

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

5

JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited; Dollars in Millions)

	Fiscal Quarter Ended	
	March 30, 2003	March 31, 2002
CASH FLOWS FROM OPERATIONS		
Net earnings	\$ 2,070	1,834
Adj. to reconcile net earnings to cash flows:		
Depreciation and amortization of property and intangibles	446	412
Purchased in-process research and development	18	-
Accounts receivable reserves	(5)	(13)
Changes in assets and liabilities, net of effects from acquisition of businesses:		
Increase in accounts receivable	(366)	(139)
Increase in inventories	(181)	(128)
Changes in other assets and liabilities	54	(31)
NET CASH FLOWS FROM OPERATING ACTIVITIES	2,036	1,935
CASH FLOWS FROM INVESTING ACTIVITIES		
Additions to property, plant and equipment	(408)	(350)
Proceeds from the disposal of assets	3	18
Acquisition of businesses, net of cash acquired	(258)	(28)
Purchases of investments	(1,634)	(1,689)
Sales of investments	1,417	2,023
Other	(17)	(58)
NET CASH USED BY INVESTING ACTIVITIES	(897)	(84)
CASH FLOWS FROM FINANCING ACTIVITIES		
Dividends to shareholders	(609)	(549)
Repurchase of common stock	(339)	(1,899)
Proceeds from short-term debt	221	272
Retirement of short-term debt	(354)	(156)
Proceeds from long-term debt	2	17
Retirement of long-term debt	(20)	(12)
Proceeds from the exercise of stock options	90	164
NET CASH USED BY FINANCING ACTIVITIES	(1,009)	(2,163)
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS		
	37	(9)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		
	167	(321)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		
	2,894	3,758
CASH AND CASH EQUIVALENTS,		

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

END OF PERIOD	\$ 3,061	3,437	
ACQUISITION OF BUSINESSES			
Fair value of assets acquired	285	39	
Fair value of liabilities assumed	(27)	(11)	
Net cash paid for acquisitions	\$ 258	28	

See Notes to Consolidated Financial Statements

6

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - The accompanying unaudited interim financial statements and related notes should be read in conjunction with the Consolidated Financial Statements of Johnson & Johnson and Subsidiaries (the "Company") and related notes as contained in the Annual Report on Form 10-K for the fiscal year ended December 29, 2002. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair presentation of such statements.

NOTE 2 - FINANCIAL INSTRUMENTS

As of March 30, 2003 the balance of deferred net losses on derivatives included in accumulated other comprehensive income was \$89 million after-tax. For additional information, see Note 8. The Company expects that \$89 million will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The amount ultimately realized in earnings will differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. Transactions with third parties will cause the amount in accumulated other comprehensive income to affect net earnings. The maximum length of time over which the Company is hedging is 15 months.

For the fiscal quarter ended March 30, 2003 the net impact of the hedges' ineffectiveness to the Company's financial statements was insignificant. For the fiscal quarter ended March 30, 2003 the Company recorded a net gain of \$5 million (after-tax) in the "other (income) expense, net" category of the consolidated statement of earnings, representing the impact of discontinuance of cash flow hedges because it is probable that the originally forecasted transactions will not occur by the end of the originally specified time period.

Refer to Note 8 for disclosures of movements in Accumulated Other Comprehensive Income.

NOTE 3 - INCOME TAXES

The effective income tax rates for the first fiscal three months of 2003 and 2002 were 29.3% and 30.0%, respectively, as compared to the U.S. federal statutory rate of 35%. The difference from the statutory rate was primarily the result of subsidiaries manufacturing in Ireland under an incentive tax rate effective through the year 2010 and domestic subsidiaries operating in Puerto Rico under a tax incentive grant expiring in 2014.

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

NOTE 4 - INVENTORIES
(Dollars in Millions)

	March 30, 2003	Dec. 29, 2002
Raw materials and supplies	\$ 896	835
Goods in process	860	803
Finished goods	1,785	1,665
	\$ 3,541	3,303

7

NOTE 5 - INTANGIBLE ASSETS

Effective the beginning of fiscal year 2002 in accordance with SFAS No. 142, the Company discontinued the amortization relating to all existing goodwill and indefinite lived intangible assets. Intangible assets that have finite useful lives continued to be amortized over their useful lives. SFAS No. 142 requires that goodwill and non-amortizable intangible assets be assessed annually for impairment. The required initial assessment was completed at June 30, 2002 and no impairment was determined. This initial impairment assessment was updated in the fourth quarter of 2002 and no impairment was determined. Future impairment tests will be performed in the fourth quarter, annually.

(Dollars in Millions)

	March 30, 2003
Goodwill-gross	\$ 5,451
Less accumulated amortization	668
Goodwill - net	4,783
Trademarks (non-amortizable)- gross	1,027
Less accumulated amortization	132
Trademarks (non-amortizable)- net	895
Patents and trademarks	2,105
Less accumulated amortization	589
Patents and trademarks - net	1,516
Other amortizable intangibles - gross	3,064
Less accumulated amortization	833
Other intangibles - net	2,231
Total intangible assets - gross	11,647
Less accumulated amortization	2,222
Total intangibles - net	\$ 9,425

Goodwill as of March 30, 2003 as allocated by segment of business is as follows:

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

(Dollars in Millions)

	Consumer	Pharm	Med. Dev & Diag	Total
Goodwill, net of accumulated amortization at December 29, 2002	821	244	3,588	4,653
Acquisitions	-	76	34	110
Translation & Other	18	7	(5)	20
Goodwill at Mar. 30, 2003	839	327	3,617	4,783

The weighted average amortization periods for patents and trademarks and other intangible assets were 16 years and 18 years, respectively. The amortization expense of amortizable intangible assets for the fiscal year ended December 29, 2002 was \$405 million pre-tax and the estimated amortization expense for the five succeeding years approximates \$425 million pre-tax, per year, respectively.

8

NOTE 6 - SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS

(Dollars in Millions)

SALES BY SEGMENT OF BUSINESS

	Fiscal First Quarter		
	2003	2002	Percent Change
Consumer			
Domestic	\$ 1,000	900	11.1
International	791	704	12.4
	1,791	1,604	11.7%
Pharmaceutical			
Domestic	\$ 3,263	2,958	10.3
International	1,403	1,223	14.7
	4,666	4,181	11.6%
Med Dev & Diag			
Domestic	\$ 1,748	1,663	5.1
International	1,616	1,295	24.8
	3,364	2,958	13.7%
Domestic	\$ 6,011	5,521	8.9
International	3,810	3,222	18.2
Worldwide	\$ 9,821	8,743	12.3%

OPERATING PROFIT BY SEGMENT OF BUSINESS

	Fiscal First Quarter		
	2003	2002	Percent Change
Consumer	\$ 413	315	31.1

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

Pharmaceutical	1,859	1,664	11.7
Med. Dev. & Diag.	731	662	10.4
Segments total	3,003	2,641	13.7
Expenses not allocated to segments	(74)	(20)	
 Worldwide total	 \$ 2,929	 2,621	 11.8%

SALES BY GEOGRAPHIC AREA

	Fiscal First Quarter		
	2003	2002	Percent Change
U.S.	\$ 6,011	5,521	8.9
Europe	2,218	1,765	25.7
Western Hemisphere			
Excluding U.S.	472	481	(1.9)
Asia-Pacific, Africa	1,120	976	14.8
 Total	 \$ 9,821	 8,743	 12.3%

9

NOTE 7 - EARNINGS PER SHARE

The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal three months ended March 30, 2003 and March 31, 2002.

(Shares in Millions)

	Fiscal Quarter Ended	
	March 30, 2003	March 31, 2002
Basic net earnings per share	\$.70	.60
Average shares outstanding - basic	2,968.4	3,042.0
Potential shares exercisable under stock option plans	179.6	204.1
Less: shares which could be repurchased under treasury stock method	(144.4)	(150.9)
Convertible debt shares	14.9	20.2
Adjusted average shares outstanding - diluted	3,018.5	3,115.4
Diluted earnings per share	\$.69	.59

Diluted earnings per share calculation included the dilution effect of convertible debt that was offset by the related decrease in interest expense of \$4 million each for the first fiscal quarter ended March 30, 2003 and March 31, 2002, respectively.

Diluted earnings per share excluded 46.6 million and .2 million shares related to options for the first fiscal quarter ended March 30, 2003 and March 31, 2002, respectively as the exercise price per share of these options was greater than the average market value, resulting in an anti-dilutive effect on diluted earnings per share.

NOTE 8 - ACCUMULATED OTHER COMPREHENSIVE INCOME

The total comprehensive income for the fiscal three months ended March 30, 2003 was \$2,094 million, compared with \$1,719 million for the same period a year ago. Total comprehensive income included net earnings, net unrealized currency gains and losses on

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

translation, net unrealized gains and losses on available for sale securities, pension liability adjustments and net gains and losses on derivative instruments qualifying and designated as cash flow hedges. The following table sets forth the components of accumulated other comprehensive income.

	For. Cur. Trans.	Unrld Gains/ (Losses) on Sec	Pens Liab Adj.	Gains/ (Losses) on Deriv & Hedg	Total Accum Other Comp
Inc/(Loss)					
December 29, 2002	\$ (707)	(2)	(33)	(100)	(842)
2003 Three Months changes					
Net change associated to current period hedging transactions	-	-	-	(6)	
Net amount reclassified to net earnings	-	-	-	17*	
Net Three Months changes	18	(5)	-	11	24
March 30, 2003	\$ (689)	(7)	(33)	(89)	(818)

Note: All amounts, other than foreign currency translation, are net of tax. Foreign currency translation adjustments are not currently adjusted for income taxes, as they relate to permanent investments in non-US subsidiaries.

*Primarily offset by changes in value of the underlying transactions.

10

NOTE 9 - MERGERS & ACQUISITIONS

On January 29, 2003, Johnson & Johnson acquired the assets of Orquest, Inc., a privately held biotechnology company focused on developing biologically-based implants for orthopaedics spine surgery. Orquest's principal product, HEALOS Bone Graft Material, is designed to reduce the time and pain associated with standard bone graft harvesting and represents a therapeutic advance for patients requiring bone graft material for spine fusion or other surgery.

On February 10, 2003, Johnson & Johnson acquired Orapharma, Inc., a specialty pharmaceutical company focused on the development and commercialization of unique therapeutics. Orapharma's initial product, ARESTIN, is the first locally administered, time-released antibiotic encapsulated in microspheres that controls the germs that can cause periodontal disease. The transaction was valued at approximately \$85 million, net of cash. On March 28, 2003, Johnson & Johnson acquired 3-Dimensional Pharmaceuticals, Inc., a company with a technology platform focused on the discovery and development of potential new drugs in early stage development for the treatment of cardiovascular disorders, oncology and inflammation. The transaction was valued at approximately \$88 million, net of cash. The Company incurred a pre-tax charge for in-process research and development (IPR&D) of approximately \$7 million.

The disclosure requirements of SFAS No. 141, "Business Combinations" and SFAS No. 142, "Goodwill and Other Intangible Assets" are not provided as the impact of these acquisitions did

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

not have a material effect on the Company's results of operations, cash flows or financial position.

During the first quarter, Johnson & Johnson also announced a definitive agreement to acquire Scios, Inc., a biopharmaceutical company with a marketed product for cardiovascular disease and research projects focused on auto-immune diseases. Scios' product NATRECOR is a novel agent approved for congestive heart failure and has several significant advantages over existing therapies. The transaction, valued at approximately \$2.4 billion, net of cash, was completed on April 29, 2003. The purchase price allocation is still in process and is not yet available. The Company expects to incur a pre-tax charge for In-Process Research & Development in the second quarter of 2003 in the range of between \$700 and \$800 million.

On May 6, 2003, the Company announced a definitive agreement to acquire Link Spine Group, Inc., a privately owned corporation that will provide the Company with exclusive worldwide rights to the SB Charite Artificial Disc for the treatment of spine disorders. Under the terms of the agreement, the Company will pay a \$325 million upfront payment with further contingent payments due upon achievement of regulatory and other milestones. The transaction is expected to close in the second quarter of 2003 and the Company anticipates an IPR&D charge of approximately \$175 million to be incurred in connection with this acquisition.

NOTE 10 - PRO FORMA STOCK BASED COMPENSATION

At March 30, 2003, the Company had 24 stock-based employee compensation plans. The Company accounted for those plans under the recognition and measurement principles of Accounting Principle Board Opinion No. 25 "Accounting for Stock Issued to Employees" and its related Interpretations. Compensation costs were not recorded in net income for stock options, as all options granted under those plans had an exercise price equal to the market value of the underlying common stock on the date of grant.

As required by SFAS No. 148, "Accounting for Stock-Based Compensation - Transition and Disclosure - an amendment of FASB Statement No. 123," the following table shows the estimated effect on net income and earnings per share if the Company had applied the fair value recognition provision of SFAS No. 123, "Accounting for Stock-Based Compensation," to stock-based employee compensation.

(Dollars in Millions Except Per Share Data)	March 30, 2003	March 31, 2002
Net income,		
as reported	2,070	1,834
Less:		
Compensation		
expense(1)	85	73
Pro forma	1,985	1,761
Earnings per share:		
Basic - as reported	\$.70	\$.60
- pro forma	.67	.58
Diluted - as reported	\$.69	\$.59
- pro forma	.66	.57

(1) Determined under fair value based method for all awards, net of tax.

NOTE 11 - LEGAL PROCEEDINGS

The information called for by this footnote is incorporated herein

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

by reference to Item 1 ("Legal Proceedings") included in Part II of this Report on Form 10-Q.

Item 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Operating Results

Sales

For the first fiscal quarter of 2003, worldwide sales were \$9.8 billion, an increase of 12.3% over 2002 fiscal first quarter sales of \$8.7 billion. The impact of foreign currencies accounted for 4.2% of the total reported increase of 12.3% over the same period a year ago.

Sales by domestic companies were \$6.0 billion in the first fiscal quarter of 2003, which represented an increase of 8.9%. Sales by international companies were \$3.8 billion, which represented an increase of 18.2% of which 11.3% was due to currency fluctuations.

For geographic areas throughout the world, sales increased 25.7% in Europe and 14.8% in Asia-Pacific/Africa but decreased 1.9% in the Western Hemisphere (excluding the U.S.) for the quarter.

Consumer segment sales in the quarter were \$1.8 billion, an increase of 11.7% over the same period a year ago with 9.6% of operational growth with a positive currency impact of 2.1%. Domestic sales increased by 11.1% while international sales gains of 12.4% included a positive currency impact of 4.9%. Consumer sales achieved strong growth in skin care products (NEUTROGENA(r), CLEAN & CLEAR(r) and AVEENO(r)) and SPLENDA(r) sweetener products as well as broad-based growth in the Consumer Pharmaceuticals and Wound Care franchises.

Pharmaceutical segment sales in the quarter were \$4.7 billion, an increase of 11.6% over the same period a year ago with 7.8% of this change due to operational increases and the remaining 3.8% increase related to the positive impact of currency. The domestic Pharmaceutical sales increase was 10.3% and the growth in international Pharmaceutical sales was 14.7% which included 13.0% related to the positive impact of currency.

Sales growth reflects the strong performance of REMICADE(r), a treatment for rheumatoid arthritis and Crohn's disease; RISPERDAL(r), an antipsychotic medication; DURAGESIC(r), a transdermal patch for chronic pain, and TOPAMAX(r), an anti-epileptic medication. The rate of growth of PROCRIIT, a product for the treatment of anemia, had slowed versus recent trends due to the entry of a new competitor. PROCRIIT, while still the market leader, has experienced a share decline. The competitive use of discounts and extended payment dating has moved market focus from total market development to a focus on share acquisition. The Company's positioning on PROCRIIT continues to focus on the clinical benefits of PROCRIIT.

The rate of growth of EPREX (epoetin alfa) experienced a sharp decline versus the prior year due to rare reports of Pure Red Cell Aplasia (PRCA) in chronic renal failure (CRF) patients when EPREX was administered subcutaneously. The Company has implemented steps to ensure that health care providers use the safest method of administering EPREX. These actions included the education of health care providers and patients in the proper handling of EPREX to preserve product integrity and a label change recommending intravenous versus subcutaneous dosing in chronic renal failure. The data available through the end of the year 2002 suggested that the incidence rate of PRCA had stabilized.

During the first quarter of 2003, the Company announced and completed the acquisition of 3-Dimensional Pharmaceuticals, Inc., a company with a technology platform focused on the discovery and

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

development of potential new drugs in early stage development for the treatment of cardiovascular disorders, oncology and inflammation. The transaction was valued at \$88 million, net of cash and resulted in an in-process research and development (IPR&D) charge of approximately \$7 million. Also during the quarter, the Company acquired Orapharma, Inc., a specialty pharmaceutical company focused on the development and commercialization of unique therapeutics. Orapharma's initial product, ARESTIN, is the first locally administered, time-released antibiotic encapsulated in microspheres that controls the germs that can cause periodontal disease. The transaction was valued at approximately \$85 million, net of cash.

12

The Company also received U.S. Food and Drug Administration (FDA) approval for REMICADE (infliximab) for the additional indication of long-term treatment of fistulizing Crohn's disease, a chronic inflammatory bowel disorder that commonly affects the lower part of the small and large intestine, as well as FLEXERIL (cyclobenzaprine HCl) 5 mg tablets for the treatment of muscle spasm associated with painful musculoskeletal conditions. In April 2003, the Company received FDA approval for RISPERDAL M-TAB (risperidone), a fast dissolving form of the schizophrenia medication that dissolves in seconds when placed in the mouth.

Worldwide sales in the first fiscal quarter of 2003 of \$3.4 billion in the Medical Devices & Diagnostics segment represented an increase of 13.7% over the same period a year ago with currency accounting for 5.7% of the sales growth. Domestic sales were up 5.1% and the international sales increase of 24.8% over the same period a year ago included a currency impact of 13.1%.

Strong sales growth was achieved in several franchises within this segment: DePuy's orthopaedic joint reconstruction and spinal products; Ethicon's wound care, and women's health products; and Ethicon Endo-Surgery's minimally invasive surgical products.

In the first quarter of 2003, Cordis sales increased by 14% versus the same period a year ago. Sales in the U.S. however, declined by approximately 14%, primarily attributable to a significant decline in coronary stent sales. In preparation for the launch of the CYPHER drug eluting stent, the Company has been working with customers to reduce their inventories of bare metal stents.

On April 24, 2003, the Company received approval from the FDA to market the CYPHER Sirolimus-eluting coronary stent, making it the first U.S. approved combination drug device intended to help reduce restenosis or reblockage of a treated coronary artery. The Company began shipping the product immediately after approval with the objective to provide access to as many patients and customers as soon as possible.

During the quarter, the Company completed the acquisition of Orquest, Inc., a privately held biotechnology company focused on developing biologically-based implants for orthopaedics and spine surgery. Orquest's principal product, HEALOS Bone Graft Material, is designed to reduce the time and pain associated with standard bone graft harvesting and represents a therapeutic advance for patients requiring bone graft material for spine fusion or other surgery.

Gross Profit

Gross profit margin in the first fiscal quarter of 2003 was 72.3%, an improvement of 0.4% over the gross profit margin in the same period a year ago of 71.9%. The improvement in gross profit margin

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

was primarily related to ongoing improvement related to cost control efforts.

Selling, General and Administrative Expenses

Consolidated selling, general and administrative expenses increased 14.4% over the same period a year ago. Selling, general and administrative expenses as a percent to sales were 33.1% versus 32.5% for the same period a year ago. The increase was primarily due to an increase in spending for a sales force expansion in the Pharmaceutical segment and pre-launch spending in anticipation of the CYPHER stent approval.

In-Process Research & Development

In the fiscal first quarter of 2003, the Company recorded in-process research & development (IPR&D) charges of \$15 million after-tax (\$18 million before tax) related to acquisitions. These acquisitions included Orquest, Inc., a privately-held biotechnology company focused on developing biologically-based implants for orthopaedics spine surgery and 3-Dimensional Pharmaceuticals, Inc., a company with a technology platform focused on the discovery and development of potential new drugs in early stage development for the treatment of cardiovascular diseases, oncology and inflammation.

13

Interest (Income) Expense

Interest income decreased in the first fiscal quarter of 2003 as compared to the same period a year ago due primarily to the continuing decline in U.S. interest rates. Interest expense in the first fiscal quarter of 2003 remained relatively constant as there were no significant changes in average debt balances.

Other (Income) Expense, Net

Other (income) expense included gains and losses related to the sale and write-down of certain equity securities of the Johnson & Johnson Development Corporation, losses on the disposal of fixed assets, currency gains & losses, minority interests, litigation settlement expense as well as royalty income. The favorable change of \$70 million in other (income) expense was due primarily to a lower level of one-time expenses in 2003 as compared to the same period a year ago. The most significant factors affecting the year-on-year comparisons were reductions in 2003 in the write-down of equity securities of Johnson & Johnson Development Corporation and a current year non-recurring increase in royalty income for the quarter.

Earnings Before Provision for Taxes on Income

Consolidated earnings before provision for taxes on income increased 11.8% versus the same period a year ago. The increase was due primarily to volume growth, improved gross profit margins offset by increases in spending in selling, marketing and administrative expenses due to sales force expansion and pre-launch spending in anticipation of the CYPHER stent approval.

Operating profit by segment

Consumer segment operating profit increased 31.1% over the same period a year ago and reflects an operating profit as a percent to sales improvement of 3.5%. The improvement was due primarily to

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

volume growth, leveraging of selling, promotion and administrative expenses offset by increased expenditures in advertising. Pharmaceutical segment operating profit increased 11.7% over the same period a year ago and its operating profit as a percent to sales was the same percent for the same period a year ago. The Pharmaceutical segment operating profit was negatively impacted by the cost of IPR&D related to 3-Dimensional Pharmaceuticals, Inc., acquisition and an increase in spending related to a sales force expansion.

Medical Devices & Diagnostics segment operating profit increased 10.4% over the same period a year ago and reflects an operating profit as a percent to sales decline of .7%. The margin decline was primarily due to pre-launch spending in anticipation of the CYPHER stent approval. Operating profit also includes the IPR&D associated with the acquisition of Orquest, Inc.

Provision For Taxes on Income

The effective income tax rates for the first fiscal three months of 2003 and 2002 are 29.3% and 30.0%, respectively, as compared to the U.S. federal statutory rate of 35%. The difference from the statutory rate was primarily the result of subsidiaries manufacturing in Ireland under an incentive tax rate effective through the year 2010 and domestic subsidiaries operating in Puerto Rico under a tax incentive grant expiring in 2014.

Net Income and Earnings Per Share

Worldwide net earnings for the first fiscal quarter of 2003 were \$2.1 billion, reflecting a 12.9% increase over 2002. Worldwide net earnings per share for the first fiscal quarter of 2003 equaled \$.69 per share, an increase of 16.9% from the \$.59 net earnings per share in the same period a year ago.

Cash Flows and Liquidity

Cash generated from operations and selected borrowings provided the major sources of funds for the growth of the business, including working capital, capital expenditures, acquisitions, share repurchases, dividends and debt repayments. Cash and current marketable securities were \$7.8 billion at the end of the first fiscal quarter of 2003 as compared with \$7.5 billion at year-end 2002.

Cash generated from operations amounted to \$2.0 billion in the first fiscal quarter of 2003 as compared to \$1.9 billion for the same period a year ago.

14

Capital Expenditures

Capital expenditures in the first fiscal quarter of 2003 increased to \$.4 billion or 16.6% over the same period a year ago. The increase was due primarily to expansion of manufacturing facilities to support new and existing products, investments in support of research facilities and investments in information systems across all business segments.

Dividends

On April 24, 2003, the Board of Directors declared a regular cash dividend of \$0.24 per share, payable on June 10, 2003 to shareholders of record as of May 20, 2003. This represented an increase of 17.1% and was the 41st consecutive year of cash

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

dividend increases. The Company expects to continue the practice of paying regular cash dividends.

Financial Position & Capital Resources

Total Assets & Returns

Total assets increased \$1.4 billion or 3.5% in the first fiscal quarter of 2003 versus year-end 2002. Net intangible assets in the first fiscal quarter of 2003 increased 1.9% over year-end 2002 and represented 22.4% of total assets versus 22.8% of total assets at year-end 2002. Net property, plant and equipment increased to \$8.8 billion or 1.0% and represented 21.0% of total assets versus 21.5% of total assets at year-end 2002. Shareholders' equity per share at the end of the first fiscal quarter of 2003 was \$8.10 compared with \$7.65 at year-end 2002, an increase of 5.9%.

Financing & Market Risk

Total borrowings at the end of the first fiscal quarter of 2003 was \$4.1 billion, unchanged from year-end 2002. For the first fiscal quarter of 2003, net cash (cash and current marketable securities net of debt) was \$3.7 billion. At year-end 2002, net cash (cash and current marketable securities net of debt) was \$3.3 billion. Total debt represented 14.6% of total capital (shareholders' equity and total debt) for the first fiscal quarter of 2003 and 15.4% of total capital at year-end 2002. For the period ended March 30, 2003, there were no material cash commitments. In association with the purchase of Scios, Inc., the Company issued approximately \$2.2 billion of commercial paper during April of 2003.

New Accounting Standards

In June 2001, the FASB issued SFAS No. 143, "Accounting for Asset Retirement Obligations." The Company adopted this standard in 2003 that was effective for fiscal years beginning after June 15, 2002 and it has not had a material impact on the Company's results of operations, cash flows or financial position. In June 2002, the FASB issued SFAS No. 146, "Accounting for Costs Associated with Exit or Disposal Activities" which was effective for exit or disposal activities that are initiated after December 31, 2002. The Company adopted SFAS No. 146 in the first quarter of 2003 and it has not had a material effect on the Company's results of operations, cash flows or financial position.

On November 25, 2002, the FASB issued FASB Interpretation No. 45 (FIN 45), "Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others, an interpretation of FASB Statements No. 5, 57 and 107 and Rescission of FASB Interpretation No. 34." FIN 45 clarified the requirements of FASB Statement No. 5, "Accounting for Contingencies," relating to the guarantor's accounting for, and disclosure of, the issuance of certain types of guarantees. The disclosure requirements of FIN 45 are effective for financial statements of interim or annual periods that end after December 15, 2002 and have been adopted by the Company. There is no disclosure required for the first fiscal quarter of 2003. The provisions for initial recognition and measurement are effective on a prospective basis for guarantees that are issued or modified after December 31, 2002, irrespective of the guarantor's year-end. FIN 45 required that upon issuance of a guarantee, the entity must recognize a liability for the fair value of the obligation it assumes under that guarantee. The Company's adoption of FIN 45 in 2003 has not had a material effect on the Company's results of operations, cash flows or financial position.

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

In January 2003, the FASB issued FIN 46, "Consolidation of Variable Interest Entities - an interpretation of ARB No. 51," which addresses consolidation of variable interest entities. FIN 46 expanded the criteria for consideration in determining whether a variable interest entity should be consolidated by a business entity, and requires existing unconsolidated variable interest entities (which include, but are not limited to, Special Purpose Entities, or SPEs) to be consolidated by their primary beneficiaries if the entities do not effectively disperse risks among parties involved. This interpretation applied immediately to variable interest entities created after January 31, 2003, and to variable interest entities in which an enterprise obtains an interest after that date. It applies in the first fiscal year or interim period beginning after June 15, 2003, to variable interest entities in which an enterprise holds a variable interest that it acquired before February 1, 2003. The adoption of FIN 46 is not expected to have a material effect on the Company's results of operations, cash flows or financial position.

Subsequent Events

On April 29, 2003, Johnson & Johnson announced that it had completed its acquisition of Scios Inc., a biopharmaceutical company with a marketed product for cardiovascular disease and research projects focused on auto-immune diseases. The Company acquired Scios in a cash for stock exchange and was valued at approximately \$2.4 billion, net of cash. The purchase price allocation is still in process and is not yet available. The Company expects to incur a pre-tax charge for In-Process Research & Development in the second quarter of 2003 in the range of between \$700 and \$800 million.

Scios is a biopharmaceutical company developing novel treatments for cardiovascular and inflammatory disease. The company's disease-based technology platform integrates expertise in protein biology with computational and medicinal chemistry to identify novel targets and rationally design small molecule compounds for large markets with unmet medical needs. Scios' product NATRECOR(r) is the first novel agent approved for congestive heart failure (CHF) in more than a decade. NATRECOR(r) is a recombinant form of a naturally occurring protein secreted by the heart as part of the body's response to CHF. The drug has several significant advantages over existing therapies for CHF, the single most common cause of hospitalization in the United States for patients over 65. The principal focus of Scios' research and development program is small molecule inhibitors, and includes several potential new treatments for pain and inflammatory diseases, including an advanced p-38 kinase inhibitor program.

On May 6, 2003, the Company announced a definitive agreement to acquire Link Spine Group, Inc., a privately owned corporation that will provide the Company with exclusive worldwide rights to the SB Charite Artificial Disc for the treatment of spine disorders. Under the terms of the agreement, the Company will pay a \$325 million upfront payment with further contingent payments due upon achievement of regulatory and other milestones. The transaction is expected to close in the second quarter of 2003 and the Company anticipates an IPR&D charge of approximately \$175 million to be incurred in connection with this acquisition.

CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS

This Form 10-Q contains "forward-looking statements." Forward-looking statements do not relate strictly to historical or current facts and anticipate results based on management's plans that are subject to uncertainty. Forward-looking statements may be identified by the use of words like "plans," "expects," "will," "anticipates," "estimates" and other words of similar meaning in conjunction with, among other things, discussions of future operations, financial performance, the Company's strategy for growth, product development, regulatory approvals, market position and expenditures.

Forward-looking statements are based on current expectations of future events. The Company cannot guarantee that any forward-looking statement will be accurate, although the Company believes that it has been reasonable in its expectations and assumptions. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements. Furthermore, the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments.

The Company's Annual Report on Form 10-K for the fiscal year ended December 29, 2002 contains, in Exhibit 99(b), a discussion of various factors that could cause actual results to differ from expectations. That Exhibit from the Form 10-K is incorporated in this filing by reference. The Company notes these factors as permitted by the Private Securities Litigation Reform Act of 1995.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There has been no material change in the Company's assessment of its sensitivity to market risk since its presentation set forth in Item 7A, "Quantitative and Qualitative Disclosures About Market Risk," in its Annual Report on Form 10-K for the fiscal year ended December 29, 2002.

Item 4 - CONTROLS AND PROCEDURES EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

Disclosure controls and procedures. Within 90 days before filing this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Company's disclosure controls and procedures are the controls and other procedures that the Company has designed to ensure that it records, processes, summarizes and reports in a timely manner the

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

information the Company must disclose in its reports filed under the Securities Exchange Act. William C. Weldon, Chairman and Chief Executive Officer, and Robert J. Darretta, Executive Vice President and Chief Financial Officer, reviewed and participated in this evaluation.

Based on this evaluation, Messrs. Weldon and Darretta concluded that, as of the date of their evaluation, the Company's disclosure controls and procedures were effective.

Internal controls. Since the date of the evaluation described above, there have not been any significant changes in the Company's internal controls or in other factors that could significantly affect those controls, including any corrective actions with regard to significant deficiencies and material weaknesses.

17

Part II - OTHER INFORMATION

Item 1. Legal Proceedings

The Company is involved in numerous product liability cases in the United States, many of which concern adverse reactions to drugs and medical devices. The damages claimed are substantial, and while the Company is confident of the adequacy of the warnings and instructions for use which accompany such products, it is not feasible to predict the ultimate outcome of litigation. However, the Company believes that if any liability results from such cases, it will be substantially covered by reserves established under its self-insurance program and by commercially available excess liability insurance.

One group of cases against the Company concerns the Janssen Pharmaceutica, Inc. product PROPULSIDr, which was withdrawn from general sale and restricted to limited use in 2000. In the wake of publicity about those events, numerous lawsuits have been filed against Janssen, which is a wholly owned subsidiary of the Company, and the Company regarding PROPULSIDr, in state and federal courts across the country. There are approximately 740 such cases currently pending, including the claims of approximately 5,428 plaintiffs. In the active cases, 425 individuals are alleged to have died from the use of PROPULSIDr. These actions seek substantial compensatory and punitive damages and accuse Janssen and the Company of inadequately testing for and warning about the drug's side effects, of promoting it for off-label use and of overpromotion. In addition, Janssen and the Company have entered into agreements with various plaintiffs' counsel halting the running of the statutes of limitations with respect to the potential claims of a significant number of individuals while those attorneys evaluate whether or not to sue Janssen and the Company on their behalf.

In September 2001, the first ten plaintiffs in the Rankin case, which comprises the claims of 155 PROPULSIDr plaintiffs, went to trial in state court in Claiborne County, Mississippi. The jury

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

returned compensatory damage verdicts for each plaintiff in the amount of \$10 million, for a total of \$100 million. The trial judge thereafter dismissed the claims of punitive damages. On March 4, 2002, the trial judge reduced these verdicts to a total of \$48 million, and denied the motions of Janssen and the Company for a new trial. Janssen and the Company believe these verdicts, even as reduced, are insupportable and have appealed. In the view of Janssen and the Company, the proof at trial demonstrated that none of these plaintiffs was injured by PROPULSIDr and that no basis for liability existed.

In April 2002, a state court judge in New Jersey denied plaintiffs' motion to certify a national class of PROPULSIDr users for purposes of medical monitoring and refund of the costs of purchasing PROPULSIDr. An effort to appeal that ruling has been denied. In June 2002 the federal judge presiding over the PROPULSIDr Multi-District Litigation in New Orleans, Louisiana similarly denied plaintiffs' motion there to certify a national class of PROPULSIDr users. Plaintiffs in the Multi-District Litigation have said they are preserving their right to appeal that ruling and other complaints filed against Janssen and the Company include class action allegations which could be the basis for future attempts to have classes certified.

With respect to all the various PROPULSIDr actions against them, Janssen and the Company dispute the claims in those lawsuits and are vigorously defending against them except where, in their judgment, settlement is appropriate. Janssen and the Company believe they have adequate self-insurance reserves and commercially available excess insurance with respect to these cases. In communications to the Company, the excess insurance carriers have raised certain defenses to their liability under the policies. However, in the opinion of the Company, those defenses are pro forma and lack substance and the carriers will honor their obligations under the policies either voluntarily or after litigation.

18

The Company's Ortho Biotech Inc. subsidiary was party to an arbitration proceeding filed against it in 1995 by Amgen, Ortho Biotech's licensor of U.S. non-dialysis rights to PROCRITr, in which Amgen sought to terminate Ortho Biotech's U.S. license rights and collect substantial damages based on alleged deliberate PROCRITr sales by Ortho Biotech during the early 1990s into Amgen's reserved dialysis market. On October 18, 2002, the arbitrator issued his decision rejecting Amgen's request to terminate the license and finding no material breach of the license. However, the arbitrator found that conduct by Ortho Biotech in the early 1990s, which was subsequently halted by Ortho Biotech, amounted to a non-material breach of the license and awarded Amgen \$150 million in damages which the Company expensed in the third quarter of 2002. Amgen had sought \$1.2 billion in damages. On January 24, 2003, the arbitrator ruled that Amgen was the "prevailing party" in this arbitration, entitling it to an award of reasonable attorneys' fees and costs. In March, Amgen submitted its application for fees and costs in the amount of \$91

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

million, which sum is subject to challenge by Ortho Biotech based on the issue of reasonableness. The Company expensed \$85 million in the fourth quarter of 2002 in connection with this outstanding claim.

In patent infringement actions tried in Delaware federal court in late 2000, Cordis Corporation, a subsidiary of Johnson & Johnson, obtained verdicts of infringement and patent validity, and damage awards, against Boston Scientific Corporation and Medtronic AVE, Inc., based on a number of Cordis coronary stent patents. On December 15, 2000, the jury in the damage action against Boston Scientific returned a verdict of \$324 million and on December 21, 2000 the jury in the Medtronic AVE action returned a verdict of \$271 million. These sums represent lost profit and reasonable royalty damages to compensate Cordis for infringement but do not include pre or post judgment interest. In February 2001 a hearing was held on the claims of Boston Scientific and Medtronic AVE that the patents at issue were unenforceable owing to alleged inequitable conduct before the patent office. In March and May 2002, the district judge issued post trial rulings which confirmed the validity and enforceability of the main Cordis stent patent claims but found certain other Cordis patents unenforceable. Further, the district judge granted Boston Scientific a new trial on liability and damages and vacated the verdict against Medtronic AVE on legal grounds. Appeals to the Federal Circuit Court of Appeals are underway.

The products of various Johnson & Johnson operating companies are the subject of various patent lawsuits which could potentially affect the ability of those operating companies to sell those products, require the payment of past damages and future royalties or, with respect to patent challenges by generic pharmaceutical firms, result in the introduction of generic versions of the products in question and the ensuing loss of market share. The following patent lawsuits concern important products of Johnson & Johnson operating companies. Medtronic AVE v. Cordis Corporation: This action, filed in April 2002 in federal district court in Texas and thereafter transferred to the federal district court in Delaware, asserts certain patents owned by Medtronic AVE against the Cordis BX VELOCITYT stent, which is also the stent structure used in the CYPHERT drug eluting product. No trial date has been set for this action. ACS/Guidant v. Cordis Corporation: This is an arbitration in which ACS/Guidant has asserted its Lau patents against the Cordis BX VELOCITY stent. In the event ACS/Guidant prevails, Cordis would pay a pre-negotiated royalty with respect to past and future BX VELOCITY sales; no injunction would be issued. The arbitration hearings commence in the fall. Boston Scientific Corporation (BSC) v. Cordis Corporation: This action, filed in Delaware federal court in March, asserts that the Cypher drug-eluting stent infringes the Ding patent assigned to BSC. BSC seeks damages and a permanent injunction and in addition has moved for a preliminary injunction, a hearing on which is scheduled for late July.

The following lawsuits are against generic firms that filed Abbreviated New Drug Applications (ANDAs) seeking to market

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

generic forms of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering these products. These ANDAs typically include allegations of non-infringement, invalidity and unenforceability of these patents. Ortho-McNeil Pharmaceutical, Inc. v. Barr Laboratories, Inc.: Pending in federal court in New Jersey, this action, filed in June 2000, involves Barr's effort to invalidate Ortho's patents covering its ORTHO TRICYCLEN r oral contraceptive product. Trial is scheduled to begin in July. Ortho-McNeil and Daiichi, Inc. v. Mylan Laboratories and Ortho-McNeil and Daiichi, Inc. v. Teva Pharmaceutical: These matters, the first of which was filed in February 2002 in federal court in West Virginia and the second in June 2002 in federal court in New Jersey, concern the efforts of Mylan and Teva to invalidate and establish non-infringement of the patent covering LEVAQUINr levofloxacin tablets. The patent is owned by Daiichi and exclusively licensed to Ortho-McNeil. In the Mylan case trial has been set for October 2003. No trial date has been set in the Teva matter. Ortho-McNeil Pharmaceutical, Inc. and Daiichi v. Bedford Laboratories: This matter was filed in federal district court in New Jersey in April 2003 and involves the effort of Bedford to invalidate and assert non-infringement of the same Daiichi patent on LEVAQUIN involved in the above proceedings. In this case, however, Bedford is challenging the patent's application with respect to its products which it asserts are equivalent to LEVAQUIN injection pre-mix and injection vials, rather than tablets. Janssen and ALZA v. Mylan Laboratories: This action, filed in federal district court in Vermont in January 2002, concerns Mylan's effort to invalidate and assert non-infringement and unenforceability of ALZA's patent covering the DURAGESICr product. Trial is scheduled for August 2003. Janssen Pharmaceutica NV v. Eon Labs Manufacturing: This action was filed in federal court in the Eastern District of New York in April 2001 and concerns Eon's effort to invalidate and establish non-infringement of Janssen's patent covering SPORANOXr (itraconazole). No trial date has yet been scheduled. Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: This lawsuit was filed in federal court in New Jersey in November 2002 and concerns the attempt of Kali to invalidate and establish non-infringement of Ortho-McNeil's patent covering ULTRACETr (tramadol-acetaminophen) tablets. No trial date has been set for this case. Alza v. Mylan Laboratories: This action was filed in federal district court in West Virginia in May 2003 and concerns Mylan's effort to invalidate and assert non-infringement of an Alza patent covering the DITROPAN XLr product. No trial date has been set for this case.

With respect to all of the above matters, the Johnson & Johnson operating company involved is vigorously defending the validity and asserting the infringement of its own or its licensors' patents or, where its product is accused of infringing patents held by others, defending against those claims.

The New York State Attorney General's office and the Federal Trade Commission issued subpoenas in January and February 2003 seeking documents relating to the marketing of sutures and endoscopic instruments by the Company's Ethicon, Inc. and Ethicon Endo-Surgery, Inc. subsidiaries. The Connecticut Attorney General's office has requested the same documents. These subpoenas focus on the bundling of sutures and endoscopic instruments in contracts offered to Group Purchasing Organizations and individual hospitals in which discounts are predicated on the hospital achieving specified market share targets for both categories of products. The operating companies involved are responding to the subpoenas.

Edgar Filing: JOHNSON & JOHNSON - Form 10-Q/A

The Company is also involved in a number of other patent, trademark and other lawsuits incidental to its business.

The ultimate legal and financial liability of the Company in respect to all claims, lawsuits and proceedings referred to above cannot be estimated with any certainty. However, in the opinion of management, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of these legal proceedings, net of liabilities already accrued in the Company's consolidated balance sheet, is not expected to have a material adverse effect on the Company's consolidated financial position, although the resolution in any reporting period of one or more of these matters could have a significant impact on the Company's results of operations for that period.

20

Item 5. Exhibits and Reports on Form 8-K

(a) Exhibit

Exhibit 99.3 Certifications Pursuant to Rule 13a-14
Under the Securities Exchange Act of 1934

Exhibit 99.15 Certifications Pursuant to 18 U.S.C.
Section 1350

(b) Reports on Form 8-K

A report on Form 8-K was filed on January 30, 2003, which included the Press Release on Amgen arbitration fees and expenses. Also included in this filing are the unaudited comparative supplementary sales data and condensed consolidated statements of earnings for the fiscal fourth quarter and fiscal year ended December 29, 2002.

A report on Form 8-K was filed on March 12, 2003, which included the audited consolidated financial statements for the three year period ended December 29, 2002.

A report on Form 8-K was filed on April 15, 2003, which included the Press Release for the period ended March 30, 2003. Also included in this filing are the unaudited comparative supplementary sales data and condensed consolidated statement of earnings for the fiscal first quarter.

A report on Form 8-K was filed on April 29, 2003, which included a reconciliation of non-GAAP disclosures included in Form 10-K for the fiscal year ended December 29, 2002.

21

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

JOHNSON & JOHNSON
(Registrant)

Date: May 15, 2003

By /s/ R. J. DARRETTA
R. J. DARRETTA
Executive Vice President and
Chief Financial Officer

Date: May 15, 2003

By /s/ S. J. COSGROVE
S. J. COSGROVE
Controller
(Chief Accounting Officer)

